Cizzle Biotechnology announces cancer-fighting partnership with Fujirebio Diagnostics.

University of York spin-out Cizzle Biotechnology has given US-based life sciences firm Furjirebio Diagnostics exclusive rights to blood testing patents and technology developed at the University of York which detect early-stage lung cancer.

The two firms will work together on a commercially valid blood test with the aim to commercialise the kit for worldwide use.

York research indicates that an altered form of a protein, called Ciz1, is present in lung cancers and can be detected through blood analysis at…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?